{"id":63305,"date":"2026-04-16T17:30:15","date_gmt":"2026-04-16T09:30:15","guid":{"rendered":"https:\/\/flcube.com\/?p=63305"},"modified":"2026-04-16T17:30:16","modified_gmt":"2026-04-16T09:30:16","slug":"3sbio-and-tigermed-forge-strategic-alliance-to-create-full-chain-pharmaceutical-innovation-ecosystem","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63305","title":{"rendered":"3SBio and Tigermed Forge Strategic Alliance to Create Full-Chain Pharmaceutical Innovation Ecosystem"},"content":{"rendered":"\n<p><strong>3SBio Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1530:HKG\">HKG: 1530<\/a>) and <strong>Hangzhou Tigermed Consulting Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/300347:SHE\">SHE: 300347<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/3347:HKG\">HKG: 3347<\/a>), China&#8217;s leading Contract Research Organization (CRO), have announced a comprehensive strategic partnership spanning <strong>innovative drug research and development (R&amp;D)<\/strong>, <strong>clinical services<\/strong>, and <strong>industrial investment<\/strong>. The collaboration aims to establish a new ecosystem for pharmaceutical innovation cooperation through synergistic integration of both companies&#8217; core competencies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-framework\">Partnership Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>3SBio Contribution<\/th><th>Tigermed Contribution<\/th><\/tr><\/thead><tbody><tr><td><strong>R&amp;D Expertise<\/strong><\/td><td>Innovative drug R&amp;D capabilities and product pipelines<\/td><td>Clinical development design and regulatory strategy<\/td><\/tr><tr><td><strong>Operational Resources<\/strong><\/td><td>Industrial resources and manufacturing infrastructure<\/td><td>Global multicenter trial execution capabilities<\/td><\/tr><tr><td><strong>Investment Focus<\/strong><\/td><td>Pipeline asset development and commercialization<\/td><td>Investment incubation and technology fund access<\/td><\/tr><tr><td><strong>Strategic Evolution<\/strong><\/td><td>From &#8220;point-based collaboration&#8221; to &#8220;full-chain coordination&#8221;<\/td><td>Comprehensive coverage across R&amp;D-to-industrialization continuum<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-governance-structure-amp-implementation\">Governance Structure &amp; Implementation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Joint R&amp;D Management Committee:<\/strong> Established to coordinate execution of key strategic projects and resource allocation<\/li>\n\n\n\n<li><strong>Dedicated Project Teams:<\/strong> Cross-functional teams formed to jointly conduct R&amp;D planning and clinical trial design<\/li>\n\n\n\n<li><strong>Funding Collaboration:<\/strong> Joint applications for national and provincial technology innovation fund projects<\/li>\n\n\n\n<li><strong>Timeline:<\/strong> Initial projects to commence Q3 2026, with full-chain coordination model implementation targeted for 2027<\/li>\n<\/ul>\n\n\n\n<p>The partnership represents a significant evolution in China&#8217;s biopharmaceutical collaboration model, moving beyond traditional CRO-client relationships toward integrated innovation ecosystems that span the entire drug development lifecycle.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-3sbio-inc\">For 3SBio Inc.<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pipeline Acceleration:<\/strong> Leverages Tigermed&#8217;s global clinical trial expertise to expedite development timelines for innovative assets<\/li>\n\n\n\n<li><strong>Regulatory Optimization:<\/strong> Gains access to Tigermed&#8217;s established regulatory filing capabilities for domestic and international markets<\/li>\n\n\n\n<li><strong>Resource Efficiency:<\/strong> Reduces operational burden through shared infrastructure and expertise across the development continuum<\/li>\n\n\n\n<li><strong>Innovation Funding:<\/strong> Enhanced access to government and private innovation funding through joint applications<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-hangzhou-tigermed\">For Hangzhou Tigermed<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Asset Depth:<\/strong> Secures long-term pipeline visibility through strategic partnership with established biopharmaceutical innovator<\/li>\n\n\n\n<li><strong>Service Integration:<\/strong> Expands beyond traditional CRO services to include investment incubation and industrialization support<\/li>\n\n\n\n<li><strong>Market Differentiation:<\/strong> Establishes leadership position in China&#8217;s evolving &#8220;full-chain&#8221; pharmaceutical innovation model<\/li>\n\n\n\n<li><strong>Revenue Diversification:<\/strong> Creates opportunities for equity participation and milestone-based compensation beyond fee-for-service<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-industry-implications\">Market Context &amp; Industry Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Biopharma Landscape:<\/strong> Domestic innovative drug development accelerating, with 42 Class 1 new drugs approved in 2025 (up 35% YoY)<\/li>\n\n\n\n<li><strong>CRO Market Evolution:<\/strong> Traditional service providers increasingly transitioning to strategic partners with integrated capabilities<\/li>\n\n\n\n<li><strong>Government Support:<\/strong> Strong policy backing for &#8220;industry-academia-research&#8221; collaboration models through National Key R&amp;D Programs<\/li>\n\n\n\n<li><strong>Investment Climate:<\/strong> Growing availability of specialized funds targeting late-stage preclinical and early clinical assets<\/li>\n<\/ul>\n\n\n\n<p>&#8220;This partnership transcends conventional collaboration boundaries,&#8221; said Dr. Wenbo Fu, Chairman and CEO of 3SBio. &#8220;By integrating our innovative R&amp;D capabilities with Tigermed&#8217;s world-class clinical development expertise, we&#8217;re creating a new paradigm for pharmaceutical innovation that will accelerate the delivery of breakthrough therapies to patients.&#8221;<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding partnership implementation, project timelines, and strategic objectives. Actual results may differ due to risks including regulatory changes, competitive dynamics, funding availability, and execution challenges in complex multi-party collaborations.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>3SBio Inc. (HKG: 1530) and Hangzhou Tigermed Consulting Co., Ltd. (SHE: 300347, HKG: 3347), China&#8217;s&#8230;<\/p>\n","protected":false},"author":1,"featured_media":63307,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[116,1061,949,948,244],"class_list":["post-63305","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-3sbio","tag-hkg-1530","tag-hkg-3347","tag-she-300347","tag-tigermed"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>3SBio and Tigermed Forge Strategic Alliance to Create Full-Chain Pharmaceutical Innovation Ecosystem - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"3SBio Inc. (HKG: 1530) and Hangzhou Tigermed Consulting Co., Ltd. (SHE: 300347, HKG: 3347), China&#039;s leading Contract Research Organization (CRO), have announced a comprehensive strategic partnership spanning innovative drug research and development (R&amp;D), clinical services, and industrial investment. The collaboration aims to establish a new ecosystem for pharmaceutical innovation cooperation through synergistic integration of both companies&#039; core competencies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63305\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"3SBio and Tigermed Forge Strategic Alliance to Create Full-Chain Pharmaceutical Innovation Ecosystem\" \/>\n<meta property=\"og:description\" content=\"3SBio Inc. (HKG: 1530) and Hangzhou Tigermed Consulting Co., Ltd. (SHE: 300347, HKG: 3347), China&#039;s leading Contract Research Organization (CRO), have announced a comprehensive strategic partnership spanning innovative drug research and development (R&amp;D), clinical services, and industrial investment. The collaboration aims to establish a new ecosystem for pharmaceutical innovation cooperation through synergistic integration of both companies&#039; core competencies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63305\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-16T09:30:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-16T09:30:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1602.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63305#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63305\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"3SBio and Tigermed Forge Strategic Alliance to Create Full-Chain Pharmaceutical Innovation Ecosystem\",\"datePublished\":\"2026-04-16T09:30:15+00:00\",\"dateModified\":\"2026-04-16T09:30:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63305\"},\"wordCount\":500,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63305#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1602.webp\",\"keywords\":[\"3SBio\",\"HKG: 1530\",\"HKG: 3347\",\"SHE: 300347\",\"Tigermed\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63305#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63305\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63305\",\"name\":\"3SBio and Tigermed Forge Strategic Alliance to Create Full-Chain Pharmaceutical Innovation Ecosystem - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63305#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63305#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1602.webp\",\"datePublished\":\"2026-04-16T09:30:15+00:00\",\"dateModified\":\"2026-04-16T09:30:16+00:00\",\"description\":\"3SBio Inc. (HKG: 1530) and Hangzhou Tigermed Consulting Co., Ltd. (SHE: 300347, HKG: 3347), China's leading Contract Research Organization (CRO), have announced a comprehensive strategic partnership spanning innovative drug research and development (R&D), clinical services, and industrial investment. The collaboration aims to establish a new ecosystem for pharmaceutical innovation cooperation through synergistic integration of both companies' core competencies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63305#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63305\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63305#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1602.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1602.webp\",\"width\":1080,\"height\":608,\"caption\":\"3SBio and Tigermed Forge Strategic Alliance to Create Full-Chain Pharmaceutical Innovation Ecosystem\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63305#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"3SBio and Tigermed Forge Strategic Alliance to Create Full-Chain Pharmaceutical Innovation Ecosystem\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"3SBio and Tigermed Forge Strategic Alliance to Create Full-Chain Pharmaceutical Innovation Ecosystem - Insight, China&#039;s Pharmaceutical Industry","description":"3SBio Inc. (HKG: 1530) and Hangzhou Tigermed Consulting Co., Ltd. (SHE: 300347, HKG: 3347), China's leading Contract Research Organization (CRO), have announced a comprehensive strategic partnership spanning innovative drug research and development (R&D), clinical services, and industrial investment. The collaboration aims to establish a new ecosystem for pharmaceutical innovation cooperation through synergistic integration of both companies' core competencies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63305","og_locale":"en_US","og_type":"article","og_title":"3SBio and Tigermed Forge Strategic Alliance to Create Full-Chain Pharmaceutical Innovation Ecosystem","og_description":"3SBio Inc. (HKG: 1530) and Hangzhou Tigermed Consulting Co., Ltd. (SHE: 300347, HKG: 3347), China's leading Contract Research Organization (CRO), have announced a comprehensive strategic partnership spanning innovative drug research and development (R&D), clinical services, and industrial investment. The collaboration aims to establish a new ecosystem for pharmaceutical innovation cooperation through synergistic integration of both companies' core competencies.","og_url":"https:\/\/flcube.com\/?p=63305","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-16T09:30:15+00:00","article_modified_time":"2026-04-16T09:30:16+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1602.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63305#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63305"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"3SBio and Tigermed Forge Strategic Alliance to Create Full-Chain Pharmaceutical Innovation Ecosystem","datePublished":"2026-04-16T09:30:15+00:00","dateModified":"2026-04-16T09:30:16+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63305"},"wordCount":500,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=63305#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1602.webp","keywords":["3SBio","HKG: 1530","HKG: 3347","SHE: 300347","Tigermed"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63305#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63305","url":"https:\/\/flcube.com\/?p=63305","name":"3SBio and Tigermed Forge Strategic Alliance to Create Full-Chain Pharmaceutical Innovation Ecosystem - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=63305#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=63305#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1602.webp","datePublished":"2026-04-16T09:30:15+00:00","dateModified":"2026-04-16T09:30:16+00:00","description":"3SBio Inc. (HKG: 1530) and Hangzhou Tigermed Consulting Co., Ltd. (SHE: 300347, HKG: 3347), China's leading Contract Research Organization (CRO), have announced a comprehensive strategic partnership spanning innovative drug research and development (R&D), clinical services, and industrial investment. The collaboration aims to establish a new ecosystem for pharmaceutical innovation cooperation through synergistic integration of both companies' core competencies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63305#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63305"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=63305#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1602.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1602.webp","width":1080,"height":608,"caption":"3SBio and Tigermed Forge Strategic Alliance to Create Full-Chain Pharmaceutical Innovation Ecosystem"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63305#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"3SBio and Tigermed Forge Strategic Alliance to Create Full-Chain Pharmaceutical Innovation Ecosystem"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1602.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63305","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63305"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63305\/revisions"}],"predecessor-version":[{"id":63308,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63305\/revisions\/63308"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/63307"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63305"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63305"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63305"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}